Platelet function monitoring in patients on clopidogrel

D. Aradi, Orsolya Rideg, A. Komócsi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clopidogrel is essential to prevent recurrent ischemic events in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). However, platelet reactivity after clopidogrel treatment is not uniform, and high on-treatment platelet reactivity (HTPR) persists in approximately one third of patients receiving clopidogrel. As recent observational studies suggest that HTPR is associated with higher risk of ischemic events, including cardiovascular death, myocardial infarction and stent thrombosis, it seems rational to monitor post-clopidogrel platelet reactivity for risk assessment and to tailor anti-platelet therapy for patients with HTPR. However, routine platelet function monitoring is not recommended by current clinical guidelines. The article aims to review the available evidence on the clinical relevance of platelet function monitoring, highlighting possible reasons for the conflict between guidelines and observational studies.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalInterventional Medicine and Applied Science
Volume3
Issue number1
DOIs
Publication statusPublished - Mar 1 2011

Fingerprint

clopidogrel
Physiologic Monitoring
Blood Platelets
Observational Studies
Guidelines
Therapeutics
Percutaneous Coronary Intervention
Acute Coronary Syndrome

Keywords

  • clopidogrel
  • PCI
  • platelet function testing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Platelet function monitoring in patients on clopidogrel. / Aradi, D.; Rideg, Orsolya; Komócsi, A.

In: Interventional Medicine and Applied Science, Vol. 3, No. 1, 01.03.2011, p. 32-38.

Research output: Contribution to journalArticle

@article{ec8806b390af4db2b81620a89f3735ff,
title = "Platelet function monitoring in patients on clopidogrel",
abstract = "Clopidogrel is essential to prevent recurrent ischemic events in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). However, platelet reactivity after clopidogrel treatment is not uniform, and high on-treatment platelet reactivity (HTPR) persists in approximately one third of patients receiving clopidogrel. As recent observational studies suggest that HTPR is associated with higher risk of ischemic events, including cardiovascular death, myocardial infarction and stent thrombosis, it seems rational to monitor post-clopidogrel platelet reactivity for risk assessment and to tailor anti-platelet therapy for patients with HTPR. However, routine platelet function monitoring is not recommended by current clinical guidelines. The article aims to review the available evidence on the clinical relevance of platelet function monitoring, highlighting possible reasons for the conflict between guidelines and observational studies.",
keywords = "clopidogrel, PCI, platelet function testing",
author = "D. Aradi and Orsolya Rideg and A. Kom{\'o}csi",
year = "2011",
month = "3",
day = "1",
doi = "10.1556/IMAS.3.2011.1.7",
language = "English",
volume = "3",
pages = "32--38",
journal = "Interventional Medicine and Applied Science",
issn = "2061-1617",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Platelet function monitoring in patients on clopidogrel

AU - Aradi, D.

AU - Rideg, Orsolya

AU - Komócsi, A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Clopidogrel is essential to prevent recurrent ischemic events in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). However, platelet reactivity after clopidogrel treatment is not uniform, and high on-treatment platelet reactivity (HTPR) persists in approximately one third of patients receiving clopidogrel. As recent observational studies suggest that HTPR is associated with higher risk of ischemic events, including cardiovascular death, myocardial infarction and stent thrombosis, it seems rational to monitor post-clopidogrel platelet reactivity for risk assessment and to tailor anti-platelet therapy for patients with HTPR. However, routine platelet function monitoring is not recommended by current clinical guidelines. The article aims to review the available evidence on the clinical relevance of platelet function monitoring, highlighting possible reasons for the conflict between guidelines and observational studies.

AB - Clopidogrel is essential to prevent recurrent ischemic events in patients with acute coronary syndromes and after percutaneous coronary interventions (PCIs). However, platelet reactivity after clopidogrel treatment is not uniform, and high on-treatment platelet reactivity (HTPR) persists in approximately one third of patients receiving clopidogrel. As recent observational studies suggest that HTPR is associated with higher risk of ischemic events, including cardiovascular death, myocardial infarction and stent thrombosis, it seems rational to monitor post-clopidogrel platelet reactivity for risk assessment and to tailor anti-platelet therapy for patients with HTPR. However, routine platelet function monitoring is not recommended by current clinical guidelines. The article aims to review the available evidence on the clinical relevance of platelet function monitoring, highlighting possible reasons for the conflict between guidelines and observational studies.

KW - clopidogrel

KW - PCI

KW - platelet function testing

UR - http://www.scopus.com/inward/record.url?scp=84858292416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858292416&partnerID=8YFLogxK

U2 - 10.1556/IMAS.3.2011.1.7

DO - 10.1556/IMAS.3.2011.1.7

M3 - Article

AN - SCOPUS:84858292416

VL - 3

SP - 32

EP - 38

JO - Interventional Medicine and Applied Science

JF - Interventional Medicine and Applied Science

SN - 2061-1617

IS - 1

ER -